The U.S. Food and Drug Administration (FDA) has granted fast track status to a combination of lunresertib and zedoresertib — two therapies in development by…
Gynecological cancer
In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…
A new regimen using the immunotherapy Keytruda (pembrolizumab) has been approved in the European Union for use by certain people with hard-to-treat gynecological…
A test that uses artificial intelligence (AI) to analyze genetic data from a vaginal swab can detect endometrial cancer with high diagnostic accuracy, a new…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…
Researchers have developed a new cell therapy that aims to treat endometrial cancer by targeting cancer cells while also depleting immune cells that help protect…
A combination of two immune-modulating treatments, Lymphir (denileukin diftitox) and Keytruda (pembrolizumab), was well tolerated in an exploratory clinical trial of people with hard-to-treat…
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC)…
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option: The U.S. Food and Drug…
